PRCC

Across TCGA pan-cancer cohorts, PRCC Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PRCC data layer compared with 23 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher PRCC Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PRCC expression acts as an unfavorable survival marker, although some lineages such as LIHC and SKCM show a favorable association.

HNSC, LUAD, and BLCA are the cancer types where PRCC Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	III,IV	0.138	0.726	.001	24	view →
LUAD	OS	Median	All	0.307	0.813	<.001	24	view →
BLCA	OS	Median	All	0.149	0.687	.005	18	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
LIHC	DFS	Median	All	1.000	0.278	.047	1	view →
SKCM	OS	Median	II,III,IV	1.000	0.726	.041	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PRCC–HNSC (OS)

Open the HNSC breakdown →